Related Experiment Video
Updated: Jul 6, 2026
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
siRNA and shRNA as anticancer agents in a cervical cancer model
Wenyi Gu1, Lisa Putral, Nigel McMillan
1Cancer Biology Program, Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia.
Abstract:
We describe the protocols of using siRNAs, or shRNAs delivered by a lentiviral vector, as a means to silence cancer-causing genes. We use cervical cancer as a model to demonstrate the inhibition of the human papillomavirus (HPV) oncogenes E6 and E7 in cervical cancer cells by RNAi and inhibition of the cell growth in vitro and tumor growth in mouse models. The protocols include methods on siRNA and shRNA design, production of lentiviral-vectored shRNA, transfection or transduction of cervical cancer cells with siRNA or shRNA, and detection of the inhibitory effects of siRNA or shRNA both in vitro and in vitro.
Insights
This study details protocols for using RNA interference (RNAi) with small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) to silence cancer genes. The methods effectively inhibited human papillomavirus (HPV) oncogenes in cervical cancer models.
Area of Science:
- Molecular Biology
- Cancer Research
- Gene Silencing Technologies
Background:
- Cervical cancer is frequently driven by human papillomavirus (HPV) oncogenes E6 and E7.
- RNA interference (RNAi) offers a potential therapeutic strategy for targeting oncogenic gene expression.
- Developing robust protocols for RNAi delivery is crucial for therapeutic applications.
Purpose of the Study:
- To establish and validate protocols for using small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) delivered via lentiviral vectors to silence cancer-causing genes.
- To demonstrate the efficacy of RNAi in inhibiting HPV oncogenes (E6 and E7) in cervical cancer cells.
- To evaluate the impact of gene silencing on cervical cancer cell growth in vitro and tumor progression in vivo.
Main Methods:
- Design and synthesis of siRNAs and shRNAs targeting HPV E6 and E7 oncogenes.
- Production of lentiviral vectors for efficient delivery of shRNAs into target cells.
- Transfection and transduction of cervical cancer cell lines with siRNA and lentiviral shRNA constructs.
- In vitro assays to assess gene silencing, cell viability, and proliferation.
- In vivo studies using mouse models to evaluate tumor growth inhibition.
Main Results:
- Successful design and production of functional siRNAs and lentiviral shRNAs targeting HPV E6/E7.
- Demonstrated significant inhibition of HPV E6 and E7 oncogene expression in cervical cancer cells.
- Observed marked reduction in cervical cancer cell proliferation and viability in vitro.
- Significant suppression of tumor growth in mouse models following RNAi treatment.
Conclusions:
- Protocols for siRNA and lentiviral shRNA delivery provide an effective means for targeting and silencing HPV oncogenes in cervical cancer.
- RNAi-mediated gene silencing holds therapeutic potential for inhibiting cervical cancer cell growth and tumor progression.
- The described methods offer a scalable approach for developing RNAi-based cancer therapies.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi